Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 1 |
2014 | 1 |
2015 | 1 |
2016 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Oncogene. 2013 Sep 12;32(37):4427-35. doi: 10.1038/onc.2012.446. Epub 2012 Oct 8.
Oncogene. 2013.
PMID: 23045273
Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). ...Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer cells. Treatment with Aki1 s …
Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to E …
Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
Yamada T, Amann JM, Fukuda K, Takeuchi S, Fujita N, Uehara H, Iwakiri S, Itoi K, Shilo K, Yano S, Carbone DP.
Yamada T, et al.
Cancer Res. 2015 Oct 1;75(19):4188-97. doi: 10.1158/0008-5472.CAN-15-0858. Epub 2015 Aug 20.
Cancer Res. 2015.
PMID: 26294214
Free PMC article.
Because current treatment options are largely ineffective, novel therapeutic strategies based on molecular mechanisms and the disease characteristics are needed to improve the outcomes of patients with this disease. Akt kinase interacting protein 1 (Aki1; Freud-1/CC2D1A) i …
Because current treatment options are largely ineffective, novel therapeutic strategies based on molecular mechanisms and the disease charac …
Item in Clipboard
Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB.
Zhang G, et al.
Sci Signal. 2016 Oct 18;9(450):rs12. doi: 10.1126/scisignal.aaf5011.
Sci Signal. 2016.
PMID: 27811184
Free PMC article.
Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but acquired resistance inevitably arises. ...Using affinity purification coupled with mass spectrometry in an ALK fusion lung cancer cell …
Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but ac …
Item in Clipboard
Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.
Ohtsubo K, Yamada T, Zhao L, Jin TF, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Fujita N, Kitagawa H, Ohta T, Ikeda H, Yano S.
Ohtsubo K, et al.
Pancreas. 2014 Oct;43(7):1093-100. doi: 10.1097/MPA.0000000000000168.
Pancreas. 2014.
PMID: 25036909
OBJECTIVES: Akt kinase-interacting protein 1 (Aki1) has been reported to be a scaffold protein of the PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt pathway and to interact with epidermal growth factor receptor signaling. Although Aki1 has …
OBJECTIVES: Akt kinase-interacting protein 1 (Aki1) has been reported to be a scaffold protein of the PI3K (phosphoinositide 3-kinase)/PDK1 …
Item in Clipboard
Cite
Cite